...residual royalty interest in cystic fibrosis treatments from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) owned by the Cystic Fibrosis Foundation...
...PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly Asia Ventures Shiyu Capital South China Venture Capital Royalty Pharma plc Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation DBV...

...pain associated with diabetic peripheral neuropathy.CF Foundation investing in Synspira programsSynspira Therapeutics Inc. said the Cystic Fibrosis Foundation...

...commits $20M to jump-start genetic therapies for cystic fibrosis  By stephen hansen, associate editor The Cystic Fibrosis Foundation’s...
...charity is hoping to partner with other VCs to broaden the early-stage CF development pipeline.The Cystic Fibrosis Foundation...
...launched last year that aims to develop therapies for those patients within the 10% (see “Cystic Fibrosis Foundation...

...see “Sagard Gaining Healthcare Foothold Via Royalty Fund” ). CF Foundation, Longwood launch incubator The Cystic Fibrosis Foundation...
...Bonanos, Associate Editor BioCentury Staff EDIT-101, lca10, AGN-151587 Editas Medicine Inc. AbbVie Inc. Allergan plc Beam Therapeutics Inc. Tangen Biosciences Inc. Trobix Innovation Ltd. Cystic Fibrosis Foundation Longwood...

...led by Viking Global Investors. Also participating were new investors Amzak Health, Casdin Capital, the Cystic Fibrosis Foundation...

...antimicrobial drug Montana-based Microbion Corp. received up to $17.1 million in grants from CARB-X and Cystic Fibrosis Foundation...

...of the disease, in large part because of R&D partnerships directed and funded by The Cystic Fibrosis Foundation...

...creating long-term financial stability for ACS, Bob Crutchfield, its managing director, told BioCentury. Unlike the Cystic Fibrosis Foundation...

...to upstage the small molecules with new modalities like mRNA or one-and-done curative approaches. The Cystic Fibrosis Foundation...
...to fund R&D therapies for patients whose genotypes aren’t treated by Vertex’s marketed drugs. (see “Cystic Fibrosis Foundation...
...no possibility of doing a long-term placebo. I think it would be unethical.” Michael Boyle, Cystic Fibrosis Foundation...

...Following the approval of Vertex’s triple therapy last week, the Cystic Fibrosis Foundation is launching a $500 million...
...on.” CFF is calling upon potential collaborators to submit proposals. Stephen Hansen, Associate Editor VX-445/tezacaftor/ivacaftor (VX-445/VX-661/VX-770) Vertex Pharmaceuticals Inc. Cystic Fibrosis Foundation...